Newsletter | November 4, 2021

11.04.21 -- Spray Dry Manufacturing And Inhaled Formulations

 
Spray-Dry Manufacturing Formulations For Local Lung Cancer Treatment
 

Lung cancer accounts for 23% of all cancer-related deaths in American adults. Though several monoclonal antibody (mAb) treatments utilizing parenteral delivery have been commercialized, local delivery has been impossible. Recent advances in spray-drying technology show promising results and potentially facilitate more effective mAbs through direct delivery to the lung.

Local Treatment Of Non-Small Cell Lung Cancer With A Spray-Dried Bevacizumab Formulation
 

Local delivery of biotherapeutics to the lung holds great promise for the treatment of lung diseases, but development of physically stable, biologically active dry powder formulations of large molecules for inhalation has remained a challenge.

Spray-Dried Dispersions Enable Local Delivery For Lung Cancer
 

Spray drying is particularly advantageous for manufacturing particles in the inhalable range of 1-5 microns. Learn more about spray drying through two case studies of inhaled dry powders.

Manufacturing Dry Powder Inhaled Formulations By Spray Drying
 

Kimberly Shepard, Ph.D., principal engineer, answers questions about how spray drying can address many challenges associated with late-stage lung cancer treatments.